Regeneron Pharmaceuticals will pay $800 million to a Cambridge biotech to leverage its genesilencing technique for the development of new therapies. httpsbuff.ly2UpH0QDÂ

Regeneron Pharmaceuticals will pay $800 million to a Cambridge #biotech to leverage its gene-silencing technique for the development of new therapies. https://buff.ly/2UpH0QD 

21:00 EDT 8 Apr 2019 | STAT

Regeneron Pharmaceuticals will pay $800 million to a Cambridge #biotech to leverage its gene-silencing technique for the development of new therapies. https://buff.ly/2UpH0QD 

More From BioPortfolio on "Regeneron Pharmaceuticals will pay $800 million to a Cambridge #biotech to leverage its gene-silencing technique for the development of new therapies. https://buff.ly/2UpH0QD "